10x Genomics (NASDAQ:TXG – Get Free Report) and Fulgent Genetics (NASDAQ:FLGT – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, profitability, analyst recommendations and dividends.
Earnings & Valuation
This table compares 10x Genomics and Fulgent Genetics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| 10x Genomics | $642.82 million | 9.07 | -$43.54 million | ($0.17) | -270.12 |
| Fulgent Genetics | $322.67 million | 1.72 | -$60.51 million | ($2.39) | -8.19 |
Profitability
This table compares 10x Genomics and Fulgent Genetics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| 10x Genomics | -3.55% | -2.86% | -2.23% |
| Fulgent Genetics | -23.04% | -3.24% | -2.97% |
Analyst Ratings
This is a summary of recent ratings and target prices for 10x Genomics and Fulgent Genetics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 10x Genomics | 1 | 10 | 4 | 0 | 2.20 |
| Fulgent Genetics | 1 | 2 | 2 | 0 | 2.20 |
10x Genomics presently has a consensus price target of $32.08, indicating a potential downside of 30.13%. Fulgent Genetics has a consensus price target of $27.00, indicating a potential upside of 37.90%. Given Fulgent Genetics’ higher possible upside, analysts plainly believe Fulgent Genetics is more favorable than 10x Genomics.
Institutional & Insider Ownership
84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 8.8% of 10x Genomics shares are held by company insiders. Comparatively, 36.2% of Fulgent Genetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk and Volatility
10x Genomics has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500.
Summary
10x Genomics beats Fulgent Genetics on 10 of the 13 factors compared between the two stocks.
About 10x Genomics
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
About Fulgent Genetics
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
